EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

LMP2A ‐Targeting CAR ‐T Cells Equipped With Inducible IL ‐18 to Address EBV ‐Associated Malignancies

Anna Christina Dragon iD, Stefanie Thoelke, Philip Mausberg, Katharina Zimmermann, Rainer Blasczyk, Michael Hudecek, Hinrich Abken, Axel Schambach, Britta Maecker-Kolhoff, Britta Eiz-Vesper iD

HLA · 2025-10 · 106 (4)

DOI: 10.1111/tan.70439 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HLA, online erschienen am 21.10.2025. Verfasst von Anna Christina Dragon und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hannover Medical School, Institute of Transfusion Medicine and Transplant Engineering, Hannover, Germany. Hauptthemen laut MEDLINE: Viral Matrix Proteins, Herpesvirus 4, Human, Interleukin-18, Epstein-Barr Virus Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hannover Biomedical Research School (HBRS), Else Kröner-Fresenius Foundation (EKFS), Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epstein–Barr virus (EBV) infects up to 95% of the world's population and persists in B cells and epithelial cells. Uncontrolled proliferation of EBV‐infected cells can result in the development of EBV‐associated malignancies, for example, post‐transplant lymphoproliferative disorder (PTLD) or nasopharyngeal cancer (NPC). It is estimated that 1.8% of deaths due to cancer worldwide are associated with EBV, and the treatment options are limited. As a new therapeutic approach, we developed chimeric antigen receptor T cells targeting EBV‐derived latent membrane protein 2A (LMP2A_CAR‐Ts). To enable specific elimination of malignant B cells infected with the intracellular pathogen, we utilised T‐cell receptor (TCR)‐like specificity to generate a CAR against the LMP2A‐derived peptide CLGGLLTMV (CLG) presented in the context of HLA‐A*02:01 . To increase functionality in the tumour microenvironment, LMP2A_CAR‐Ts were additionally equipped with inducible release of IL‐12 (LMP2A_iIL‐12_TRUCKs) or IL‐18 (LMP2A_iIL‐18_TRUCKs). LMP2A_CAR‐Ts and LMP2A_iIL‐18_TRUCKs specifically recognised HLA‐A*02:01 + EBV‐transformed B‐lymphoblastoid cell lines and HLA‐A*02:01 + cells loaded with CLG peptide (A02_CLG + cells), proving their target specificity, while, unexpectedly, LMP2A_iIL‐12_TRUCKs exhibited a disparate T EM and NK‐like phenotype and A02_CLG‐independent reactivity. In contrast, LMP2A_CAR‐Ts and LMP2A_iIL‐18_TRUCKs effectively induced T‐cell signalling, activation, release of cytotoxic mediators, including IL‐18 by LMP2A_iIL‐18_TRUCKs and mediated cytotoxicity in a target‐specific manner. Our results demonstrate that LMP2A_CAR‐Ts and LMP2A_iIL‐18_TRUCKs specifically recognise the EBV‐derived CLG peptide presented in the context of HLA‐A*02:01 . Especially, LMP2A_iIL‐18_TRUCKs with an even improved anti‐tumour response, as well as the potential to recruit bystander immune cells and overcome EBV‐mediated immune evasion strategies, might serve as a novel treatment option for various EBV‐associated malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Viral Matrix ProteinsHerpesvirus 4, HumanInterleukin-18Epstein-Barr Virus InfectionsImmunotherapy, AdoptiveReceptors, Chimeric AntigenNasopharyngeal NeoplasmsHumansTumor MicroenvironmentB-LymphocytesHLA-A2 AntigenCell Line, Tumor

Stichwörter der Autor:innen

CAR‐T cellsEBV‐associated malignanciesLMP2APTLDTCR‐like CARTCR‐like antibodyTRUCKsinducible cytokine expression

Substanzen

Viral Matrix ProteinsEBV-associated membrane antigen, Epstein-Barr virusInterleukin-18Receptors, Chimeric AntigenHLA-A2 Antigen

Autor:innen und Institutionen

  • Hannover Medical School, Institute of Transfusion Medicine and Transplant Engineering, Hannover, Germany.
  • nextGENERATION Medical Scientist Program, Dean's Office for Academic Career Development, Hannover, Germany.
  • Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
  • Cellular Immunotherapy, Department of Internal Medicine II, University of Wuerzburg, Wuerzburg, Germany.
  • Department Genetic Immunotherapy, Leibniz Institute for Immunotherapy, Regensburg, Germany.
  • Genetic Immunotherapy, University Regensburg, Regensburg, Germany.

ORCID-Profile: Anna Christina Dragon, Britta Eiz-Vesper

Förderung

  • Hannover Biomedical Research School (HBRS)
  • Else Kröner-Fresenius Foundation (EKFS)
  • Deutsche Forschungsgemeinschaft
  • German Center for Infection Research (DZIF)
  • Stiftung Deutsche Krebshilfe
  • Else Kröner-Fresenius-Stiftung
  • Deutsches Zentrum für Infektionsforschung
  • Deutsche Krebshilfe

Zitieren

APA

Dragon, A. C., Thoelke, S., Mausberg, P., Zimmermann, K., Blasczyk, R., Hudecek, M., Abken, H., Schambach, A., Maecker-Kolhoff, B., & Eiz-Vesper, B. (2025). LMP2A ‐Targeting CAR ‐T Cells Equipped With Inducible IL ‐18 to Address EBV ‐Associated Malignancies. HLA, 106(4). https://doi.org/10.1111/tan.70439

Vancouver

Dragon AC, Thoelke S, Mausberg P, Zimmermann K, Blasczyk R, Hudecek M, et al. LMP2A ‐Targeting CAR ‐T Cells Equipped With Inducible IL ‐18 to Address EBV ‐Associated Malignancies. HLA. 2025;106(4). doi:10.1111/tan.70439

BibTeX
@article{Dragon2025,
  author = {Dragon, Anna Christina and Thoelke, Stefanie and Mausberg, Philip and Zimmermann, Katharina and Blasczyk, Rainer and Hudecek, Michael and Abken, Hinrich and Schambach, Axel and Maecker-Kolhoff, Britta and Eiz-Vesper, Britta},
  title = {LMP2A ‐Targeting CAR ‐T Cells Equipped With Inducible IL ‐18 to Address EBV ‐Associated Malignancies},
  journal = {HLA},
  year = {2025},
  volume = {106},
  number = {4},
  doi = {10.1111/tan.70439}
}
Kostenlos starten →